This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

Claims 1-29 (Cancelled)

Claim 30 (Original) A method for treating an allergic condition in a subject, comprising administering a pharmaceutically effective amount of a therapeutic agent to the subject, said therapeutic agent comprising a molecule having at least a first segment competent for importation of said molecule into mast cells in vivo, and a second segment for having an anti-allergic effect within said mast cells, said first segment being joined to said second segment through a linker, whereby the complex molecule is capable of exerting its anti-allergic effect in vivo.

Claim 31 (Original) The method of claim 30, wherein the allergic condition is selected from the group consisting of nasal allergy, an allergic reaction in an eye of the subject, an allergic reactions in the skin of the subject, acute urticaria, psoriasis, psychogenic or allergic asthma, interstitial cystitis, bowel diseases, migraines and multiple sclerosis.

Claim 32 (Currently Amended) The method of claim 30 ~~31~~, wherein administration of said therapeutic agent is performed by topical administration.

Claim 33 (Original) The method of claim 32, wherein said topical administration is to the eye, the skin or to a mucus membrane of the subject.

Claim 34 (Currently Amended) The method of claim 30 ~~33~~, wherein administration of said therapeutic agent is performed by inhalation or intranasal administration.

Claim 35 (Currently Amended) The method of claim 30 ~~34~~, wherein administration of said therapeutic agent is performed by oral or systemic parenteral administration.

Claim 36 (Currently Amended) The method of claim 30 ~~32~~, wherein said second segment has said anti-allergic effect by at least significantly reducing degranulation of said mast cells.

Claim 37 (Currently Amended) The method of claim 30 ~~36~~, wherein said second segment is selected from the group consisting of a peptide, peptidomimetic or a polypeptide.

Claim 38 (Original) The method of claim 37, wherein said second segment is a peptide.

Claim 39 (Currently Amended) The method of claim 30 ~~38~~, wherein said first segment is a peptide.

Claim 40 (Currently Amended) The method of claim 30 ~~39~~, wherein said linker is a covalent bond.

Claim 41 (Original) The method of claim 40, wherein said covalent bond is a peptide bond.

Claim 42 (Currently Amended) The method of claim 30 ~~41~~, wherein said second segment is a peptide taken from the C terminal sequence of $G\alpha i_3$.

Claim 43 (Currently Amended) The method of claim 30 ~~42~~, wherein said molecule is a peptide having an amino acid sequence AAVALLPAVLLALLAPKNNLKECGLY (SEQ ID NO:7), and cyclic derivatives thereof.

Claim 44 (Currently Amended) The method of claim 30 ~~41~~, wherein said second segment is a peptide taken from the C terminal sequence of $G\alpha_t$.

Claim 45 (Currently Amended) The method of claim 30 44, wherein said molecule is a peptide having an amino acid sequence AAVALLPAVLLALLAPKENLKDCGLF (SEQ ID NO:12).

Claim 46 (Currently Amended) The method of claim 30 ~~39~~, wherein said therapeutic agent further comprises a second molecule, said second molecule being a peptide having an amino acid sequence AAVALLPAVLLALLAPKNNLKECGLY (SEQ ID NO:7).

Claim 47 (Currently Amended) The method of claim 30 ~~31~~, wherein said molecule is a peptide having an amino acid sequence Succinyl-AAVALLPAVLLALLAPKNNLKECGLY (SEQ ID NO: 8).

Claims 48-49 (Cancelled)

Claim 50 (Currently Amended) The method of claim 43 ~~31~~, wherein the molecule further comprises cyclization between lysine at position 17 and the C terminus of the peptide.

Claim 51 (Cancelled)